Latest Point Therapeutics Inc. Stories

2004-11-30 09:00:10

Point Therapeutics, Inc. (NASDAQ:POTP) today announced that it has successfully completed the first stage of the Company's Phase 2 clinical study in Stage IIIB/IV non-small cell lung cancer. The pre-established tumor response criteria have been met, allowing the Company to continue with the second stage of the study. This study is evaluating the Company's oral lead product candidate, talabostat (PT-100), in combination with Taxotere(R) in patients with advanced NSCLC who have failed a prior...

Word of the Day
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.